Similarly, the EXSCEL trial revealed that once-weekly exenatide did not significantly lower stroke incidence in patients with type 2 diabetes, though a favourable trend was observed
GLP-1 is a hormone that regulates appetite, insulin secretion, and digestion
Many patients experience substantial weight loss over 6-12 months, with an average reduction of 10-20% of their starting weight, depending on lifestyle habits and individual response to treatment
ADA Recommendations for GLP-1 RA in T2DM Patients The GLP-1 receptor agonists, with or without metformin based on glycemic needs, are appropriate initial therapy for patients with type 2 diabetes mellitus (T2DM) with or at high risk for atherosclerotic cardiovascular disease (ASCVD)/indicators of high-risk, heart failure (HF), or chronic kidney disease (CKD)
10.1016/S0140-6736(19)31149-3 46
01 Select Pack Size Choose Single, 10-Pack, 25-Pack, or request a Bulk quote at checkout